A collaborative scientific team led by researchers at the Applied Biomedical Science Institute (ABS), Scripps Research, Kansas State University (K-State), University of Louisville, OmniAb, Inc., and Ligand Pharmaceuticals has discovered and validated a potential new class of therapeutic agent based on the unique antigen binding regions of cow antibodies.
September 20, 2023
· 5 min read